X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SHASUN PHARMA - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SHASUN PHARMA BIOCON /
SHASUN PHARMA
 
P/E (TTM) x 41.1 123.9 33.1% View Chart
P/BV x 7.1 8.5 83.6% View Chart
Dividend Yield % 0.2 0.2 69.6%  

Financials

 BIOCON    SHASUN PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
SHASUN PHARMA
Mar-14
BIOCON /
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,18894 1,261.1%   
Low Rs30546 668.9%   
Sales per share (Unadj.) Rs68.7214.2 32.1%  
Earnings per share (Unadj.) Rs7.65.3 141.5%  
Cash flow per share (Unadj.) Rs14.015.8 88.3%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.11.4 9.4%  
Book value per share (Unadj.) Rs86.353.3 161.9%  
Shares outstanding (eoy) m600.0056.62 1,059.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.90.3 3,328.3%   
Avg P/E ratio x98.913.1 754.6%  
P/CF ratio (eoy) x53.44.4 1,209.4%  
Price / Book Value ratio x8.61.3 659.7%  
Dividend payout %13.218.7 70.7%   
Avg Mkt Cap Rs m447,9003,958 11,317.1%   
No. of employees `0006.1NA-   
Total wages/salary Rs m9,3112,164 430.4%   
Avg. sales/employee Rs Th6,705.8NM-  
Avg. wages/employee Rs Th1,514.2NM-  
Avg. net profit/employee Rs Th736.9NM-  
INCOME DATA
Net Sales Rs m41,23412,127 340.0%  
Other income Rs m2,062229 899.1%   
Total revenues Rs m43,29612,356 350.4%   
Gross profit Rs m8,2911,009 821.7%  
Depreciation Rs m3,851594 648.8%   
Interest Rs m615415 148.2%   
Profit before tax Rs m5,887230 2,562.9%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,569-73 -2,157.6%   
Profit after tax Rs m4,531302 1,499.7%  
Gross profit margin %20.18.3 241.7%  
Effective tax rate %26.7-31.7 -84.2%   
Net profit margin %11.02.5 441.1%  
BALANCE SHEET DATA
Current assets Rs m41,4866,884 602.6%   
Current liabilities Rs m21,4138,456 253.2%   
Net working cap to sales %48.7-13.0 -375.6%  
Current ratio x1.90.8 238.0%  
Inventory Days Days6462 103.8%  
Debtors Days Days94108 87.6%  
Net fixed assets Rs m50,6614,970 1,019.3%   
Share capital Rs m3,000113 2,647.8%   
"Free" reserves Rs m48,8082,875 1,697.7%   
Net worth Rs m51,8083,020 1,715.4%   
Long term debt Rs m17,8981,817 984.8%   
Total assets Rs m99,89713,347 748.5%  
Interest coverage x10.61.6 680.6%   
Debt to equity ratio x0.30.6 57.4%  
Sales to assets ratio x0.40.9 45.4%   
Return on assets %5.25.4 95.9%  
Return on equity %8.710.0 87.4%  
Return on capital %9.613.3 72.3%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m12,0585,843 206.4%   
Fx outflow Rs m7,3482,173 338.1%   
Net fx Rs m4,7103,669 128.4%   
CASH FLOW
From Operations Rs m6,621398 1,665.2%  
From Investments Rs m-6,840-1,635 418.3%  
From Financial Activity Rs m-2,3971,309 -183.2%  
Net Cashflow Rs m-2,61271 -3,668.5%  

Share Holding

Indian Promoters % 40.4 39.2 103.1%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 3.6 233.3%  
FIIs % 10.7 17.6 60.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 39.6 50.3%  
Shareholders   109,995 20,750 530.1%  
Pledged promoter(s) holding % 0.0 12.3 0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Get Ready for Record Highs(Podcast)

Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.

Related Views on News

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (4QFY18); Net Profit Up 19.8% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 19.8% YoY). Sales on the other hand came in at Rs 12 bn (up 25.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Mar 22, 2019 (Close)

TRACK BIOCON

BIOCON - ALEMBIC PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS